Role of Iron Deficiency and Anemia in Cardio-Renal Syndromes

Seminars in Nephrology

Volumn 32, Issue 1, 2012, Pages 57-62

  Attanasio, Philipp ^a   Ronco, Claudio ^b   Anker, Stefan D ^a,c   Cicoira, Mariantonietta ^d   von Haehling, Stephan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SAN BORTOLO HOSPITAL   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

Anemia; Chronic heart failure; Chronic kidney disease; Iron deficiency

Indexed keywords

ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FERRIC HYDROXIDE SUCROSE; FERUMOXYTOL; IRON; IRON DEXTRAN; IRON ISOMALTOSIDE; NEBIVOLOL; PLACEBO; UNCLASSIFIED DRUG; VALSARTAN;

ANAPHYLACTIC SHOCK; ARTICLE; CARDIORENAL SYNDROME; DISEASE CLASSIFICATION; DRUG EFFICACY; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANEMIA, IRON-DEFICIENCY; CARDIO-RENAL SYNDROME; CHRONIC DISEASE; ERYTHROPOIETIN; FERRIC COMPOUNDS; HEMATINICS; HUMANS; IRON;

EID: 84857438849     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2011.11.008     Document Type: Article

References (55)

1. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., et al. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010, 121:948-954. American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
2. Cowie M.R., Mosterd A., Wood D.A., Deckers J.W., Poole-Wilson P.A., Sutton G.C., et al. The epidemiology of heart failure. Eur Heart J 1997, 18:208-225.
3. Davies M., Hobbs F., Davis R., Kenkre J., Roalfe A.K., Hare R., et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001, 358:439-444.
4. von Haehling S., Lainscak M., Doehner W., Ponikowski P., Rosano G., Jordan J., et al. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle 2010, 1:187-194.
5. Coresh J., Astor B.C., Greene T., Eknoyan G., Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1-12.
6. Smith G.L., Lichtman J.H., Bracken M.B., Shlipak M.G., Phillips C.O., DiCapua P., et al. Renal impairment and outcomes in heart failure. J Am Coll Cardiol 2006, 47:1987-1996.
7. Hillege H.L., Nitsch D., Pfeffer M.A., Swedberg K., McMurray J.J., Yusuf S., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006, 113:671-678. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators.
8. Ronco C., Haapio M., House A.A., Anavekar N., Bellomo R. Cardio-renal syndrome. J Am Coll Cardiol 2008, 52:1527-1539.
9. von Haehling S., Jankowska E.A., Ponikowski P., Anker S.D. Anemia in heart failure. Future Cardiol 2011, 7:119-129.
10. Attanasio P., Anker S.D., Doehner W., von Haehling S. Hormonal consequences and prognosis of chronic heart failure. Curr Opin Endocrinol Diabetes Obesity 2011, 18:224-230.
11. von Haehling S., Anker S.D. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010, 1:1-5.
12. von Haehling S., Anker S.D. Cardio- Renal Anemia Syndrome. Contrib Nephrol 2011, 171:266-273.
13. Nutritional anaemias: report of a WHO scientific group 1968, World Health Organization, World Health Organization, Geneva, Switzerland.
14. Kazory A., Ross E.A. Anemia: the point of convergence or divergence for kidney disease and heart failure?. J Am Coll Cardiol 2009, 53:639-647.
15. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification: part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis 2002, 39:S46-S75. National Kidney Foundation.
16. El-Achkar T.M., Ohmit S.E., McCullough P.A., et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: the Kidney Early Evaluation Program. Kidney Int 2005, 67:1483-1488.
17. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007, 50:471-530. KDOQI.
18. Tang Y.D., Katz S.D. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006, 113:2454-2461.
19. Silverberg D.S., Wexler D., Iaina A. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?. J Nephrol 2004, 17:749-761.
20. Anand I.S. Pathogenesis of anemia in cardio-renal disease. Rev Cardiovasc Med 2005, 6(Suppl):S13-S21.
21. Witte K.K., Desilva R., Chattopadhyay S., Ghosh J., Cleland J.G., Clark A.L. Are hematinic deficiencies the cause of anemia in chronic heart failure?. Am Heart J 2004, 147:924-930.
22. Tang Y.D., Katz S.D. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006, 113:2454-2461.
23. von Haehling S., van Veldhuisen D.J., Roughton M., Babalis D., de Boer R.A., Coats A.J., et al. Anemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. Eur J Heart Fail 2011, 13:656-663.
24. von Haehling S., Lainscak M., Doehner W., Ponikowski P., Rosano G., Jordan J., et al. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle 2010, 1:187-194.
25. Scrutinio D., Passantino A., Santoro D., Catanzaro R. The cardio-renal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival. Eur J Heart Fail 2011, 13:61-67.
26. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
27. Groenveld H.F., Januzzi J.L., Damman K., van Wijngaarden J., Hillege H.L., van Veldhuisen D.J., et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008, 52:818-827.
28. von Haehling S., Schefold J.C., Hodoscek L.M., Doehner W., Mannaa M., Anker S.D., et al. Anaemia is an independent predictor of death in patients hospitalized for acute heart failure. Clin Res Cardiol 2010, 99:107-113.
29. Tarantini L, Oliva F, Cantoni S, Cioffi G, Agnoletto V, Alunni G, et al. Prevalence and prognostic role of anaemia in patients with acute heart failure and preserved or depressed ventricular function. Intern Emerg Med. In press.
30. Anand I.S., Kuskowski M.A., Rector T.S., Florea V.G., Glazer R.D., Hester A., et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005, 112:1121-1127.
31. Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 2003, 18(Suppl 2):7-12.
32. Adams K.F., Piña I.L., Ghali J.K., Wagoner L.E., Dunlap S.H., Schwartz T.A., et al. Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. Am Heart J 2009, 158:965-971.
33. Kalra P.R., Bolger A.P., Francis D.P., Genth-Zotz S., Sharma R., Ponikowski P.P., et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 2003, 9:888-891.
34. Go A.S., Yang J., Ackerson L.M., Lepper K., Robbins S., Massie B.M., et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006, 113:2713-2723.
35. Ezekowitz J.A., McAlister F.A., Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003, 107:223-225.
36. Joosten E. Strategies for the laboratory diagnosis of some common causes of anaemia in elderly patients. Gerontology 2004, 50:49-56.
37. Witte K.K., Clark A.L. Nutritional abnormalities contributing to cachexia in chronic illness. Int J Cardiol 2002, 85:23-31.
38. Silagy C.A., McNeil J.J., Donnan G.A., Tonkin A.M., Worsam B., Campion K. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993, 54:84-89.
39. Jankowska E.A., Rozentryt P., Witkowska A., Nowak J., Hartmann O., Ponikowska B., et al. Iron deficiency: an ominous sign in patients with systolic heart failure. Eur Heart J 2010, 31:1872-1880.
40. Nanas J.N., Matsouka C., Karageorgopoulos D., Leonti A., Tsolakis E., Drakos S.G., et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006, 48:2485-2489.
41. Hsu C.-Y., McCullough C.E., Curhan G.C. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002, 13:504-510.
42. Lankhorst C.E., Wish J.B. Anemia in renal disease: diagnosis and management. Blood Rev 2010, 24:39-47.
43. Silverberg D.S., Wexler D., Blum M., Keren G., Sheps D., Leibovitch E., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000, 35:1737-1744.
44. Silverberg D.S., Iaina A., Peer G., Kaplan E., Levi B.A., Frank N., et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996, 27:234-238.
45. Bolger A.P., Bartlett F.R., Penston H.S., O'Leary J., Pollock N., Kaprielian R., et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006, 48:1225-1227.
46. Toblli J.E., Lombraña A., Duarte P., Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007, 50:1657-1665.
47. Usmanov R.I., Zueva E.B., Silverberg D.S., Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008, 21:236-242.
48. Okonko D.O., Grzeslo A., Witkowski T., Mandal A.K., Slater R.M., Roughton M., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008, 51:103-112.
49. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. FAIR-HF committees and investigators. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail. 2009a;11:1084-91.
50. Ganzoni A.M. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970, 100:301-303.
51. Anker S.D., Comin Colet J., Filippatos G., Willenheimer R., Dickstein K., Drexler H., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009, 361:2436-2448. FAIR-HF Trial Investigators.
52. Danielson B.G. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004, 15(Suppl):S93-S98.
53. Auerbach M., Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010, 2010:338-347.
54. Wikström B., Bhandari S., Barany P., Kalra P.A., Ladefoged S., Wilske J., et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol 2011.
55. Lu M., Cohen M.H., Rieves D., Pazdur R. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 2010, 85:315-319.